Zydus Lifesciences and Lupin Limited have entered into a Licensing and Supply Agreement to co-market Zydus’ innovative Semaglutide Injection (15 mg/3 ml) in India. The partnership combines Zydus’ development capabilities with Lupin’s extensive market reach. Zydus will market the drug under the brands SEMAGLYN™, MASHEMA™, and ALTERME™, while Lupin will use Semanext® and Livarise®. The collaboration aims to enhance patient access to advanced therapies for metabolic disorders.
Strategic Partnership for Metabolic Therapies
Zydus Lifesciences Limited (Zydus) announced on March 17, 2026, that it has signed a Licensing and Supply Agreement with Lupin Limited (Lupin). This agreement focuses on expanding access to Zydus’ innovative Semaglutide Injection (15 mg/3 ml), which features a patient-friendly reusable pen device, across the Indian market.
The partnership leverages Zydus’ strong product development expertise and Lupin’s significant distribution network in India. The shared objective is to bring advanced therapies for metabolic disorders to a wider patient population.
Co-Marketing and Branding Details
Under the terms, Lupin receives semi-exclusive rights to co-market the Semaglutide Injection. The branding strategy involves multiple lines:
- Zydus will market the product under the brand names: SEMAGLYN™, MASHEMA™, and ALTERME™.
- Lupin will market the product under the brand names: Semanext® and Lupin’s Livarise®.
Lupin will provide Zydus with upfront licensing fees and milestone payments contingent upon achieving pre-defined performance goals.
Executive Commentary on Access and Impact
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., emphasized that the core focus of the innovative pen device is to simplify therapy and improve the quality of life for patients. He expressed pleasure in partnering with Lupin to broaden the medicine’s reach across India.
Nilesh Gupta, Managing Director of Lupin, stated that this collaboration strengthens Lupin’s commitment to providing advanced treatment options for cardio-metabolic diseases. He highlighted that the partnership enhances Lupin’s diabetes portfolio and reinforces their focus on addressing unmet patient needs.
Therapeutic Indications for Semaglutide
Semaglutide injection is approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Specifically, it is indicated:
- As monotherapy, when metformin is deemed inappropriate due to intolerance or contraindications.
- In addition to other medicinal products for the treatment of diabetes.
The drug is also indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults meeting specific Body Mass Index (BMI) criteria (obesity or overweight) with at least one weight-related comorbid condition.
Company Background Snippets
Zydus Lifesciences Limited is noted as an innovation-led global life sciences company with leadership across pharmaceuticals, consumer wellness, and an emerging MedTech franchise. The group employs over 29,000 people worldwide.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, distributing products in over 100 markets. Lupin maintains a strong position in India and the U.S. across several key therapy areas and employs over 24,000 professionals globally.
Source: BSE
